biologic

Xenpozyme

olipudase alfa-rpcp

Loss of exclusivityAugust 2034projected — 12-year biologic exclusivity estimate
CompanyGenzyme Corporation

Drug detail

Brand nameXenpozyme
Active ingredientolipudase alfa-rpcp
Strength20MG
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalAugust 2022
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Not found